Author

Alexander Lurie

Observed name: Alexander B. Lurie

Observed institutions: Rush University Medical Center, University of Chicago Medical Center

OpenAlex ID: A5072691898

Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis

2022 · Peter Rossing, Stefan D. Anker, et al. · Diabetes Care · 234

Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes

2023 · Rajiv Agarwal, Wanzhu Tu, et al. · Annals of Internal Medicine · 117

Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study

2022 · Peter Rossing, Ellen Burgess, et al. · Diabetes Care · 39

Comparison of Once-Daily Glargine Insulin with Twice-Daily NPH/Regular Insulin for Control of Hyperglycemia in Inpatients After Cardiovascular Surgery

2006 · Renuka R. Yeldandi, Alexander Lurie, et al. · Diabetes Technology & Therapeutics · 28

Case of aggressive metastatic follicular variant papillary thyroid carcinoma with BRAF K601E and BCORL1 mutations

2020 · Doaa Attia, Alexander Lurie, et al. · BMJ Case Reports · 5

The Epidemiology of Diabetes Mellitus: An International Perspective

2002 · Alexander B. Lurie · Medicine & Science in Sports & Exercise · 1

Erratum. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study. Diabetes Care 2022;45:888–897

2023 · Peter Rossing, Ellen Burgess, et al. · Diabetes Care

Works count: 7

Citation count: 424

H-index: 5

I10-index: 4